Table 4.
Age- and gender- adjusted vaccine effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPV23) against invasive pneumococcal disease in people ≥60 in Germany. 95% CI shows the lower and upper bounds of the 95% confidence interval of the vaccine effectiveness estimate.
| All | vaccinated <2 years prior to IPD |
vaccinated between 2 and 4 years prior to IPD |
vaccinated ≥5 years prior to IPD |
Age 60-69 |
Age 70-79 |
Age ≥80 |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VE (%) | 95% CI (%) | VE (%) | 95% CI (%) | VE (%) | 95% CI (%) | VE (%) | 95% CI (%) | VE (%) | 95% CI (%) | VE (%) | 95% CI (%) | VE (%) | 95% CI (%) | |
| PPV23 serotypes | 36 | 10,54 | -20 | -130,34 | 56 | 20,76 | 47 | 17,66 | 71 | 42,86 | 28 | -27, 58 | 12 | -53,49 |
| PPV23 serotypes except 3 | 63 | 49,74 | 49 | 12,71 | 66 | 37,82 | 69 | 50,81 | 67 | 33, 85 | 63 | 38, 79 | 60 | 32,77 |
| PPV23 serotypes except 3 and 8 | 58 | 40,70 | 52 | 16,74 | 48 | 3,73 | 65 | 42,79 | 62 | 21,83 | 59 | 28, 78 | 51 | 16,72 |
| PPV23-nonPCV13 serotypes | 59 | 42,71 | 38 | -7,66 | 67 | 36,84 | 65 | 42,79 | 78 | 50,92 | 54 | 21, 74 | 50 | 12,72 |
| Serotype 3 | -117 | -208,-53 | -179 | -384,-58 | -60 | -201,19 | -106 | -229,-26 | -1 | -117, 56 | -159 | -361, -45 | -176 | -390, -55 |
The changes to Table 4 do not impact the final analysis or conclusions of the manuscript, but there are several places in the text where there is a discrepancy between the corrected values in the table and in the original text of the manuscript. Please use the values in this corrected table in place of the values listed in the text.